Answers are grounded in this paper and cite their sources.
Background: Liver cirrhosis, the 11th death common cause, is a severe disorder that includes inflammation, oxidative damage, also immune response. Harmaline shows the antioxidant and anti-inflammatory mechanisms that aid in partial protection of hepatic cirrhosis. Objective: This work aimed to evaluate the protection effect of harmaline against liver cirrhosis induced by thioacetamide in mice via arginase-1 enzyme activity modulation. Methods: The study was carried out on forty male mice divided into four groups. Control group (GI), thioacetamide group (GII), harmaline group (GIII), and co-treated group (GIV). By the end of the experiment, arginase-1 activity and liver enzymes were measured in serum and liver tissue. Results: The results showed that combined harmaline administration can cause significant suppression of liver inflammation by increasing ariginase-1 activity to nearly normal values. Inhibition of activated myofibroblasts cells and extracellular matrix accumulation was also noticed. Conclusion: Harmaline has protective role against liver cirrhosis induced by thioacetamide in mice. It can be therapeutically used as a safe liver support after further in vivo studies.
No takes yet. Share an insight, caveat, or question.
Beltagy et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: